New Insights into the KLK2 Target: SPINT1/2 Mediate Cell Membrane Anchoring in Prostate Cancer
Human kallikrein 2 (Kallikrein 2, KLK2) is a serine protease and an increasingly prominent target in prostate cancer therapy. Structurally, KLK2 lacks a transmembrane domain[1][2]; consequently, it was traditionally classified as a secreted protein and considered difficult to drug via cell-surface targeting modalities. In 2025, researchers at Johnson & Johnson (J&J) utilized flow cytometry and confocal imaging to demonstrate that KLK2 is expressed on the cell surface of patients with bone-metastatic castration-resistant prostate cancer (mCRPC) and on the membrane of the human prostate cancer cell line VCaP[3].
This observation raised a fundamental question: given that KLK2 lacks an intrinsic transmembrane domain, how is it anchored to the prostate tumor cell membrane? A 2025 study and subsequent patent disclosure (WO2026/074493) highlight a proposed molecular mechanism underlying KLK2 membrane localization. Recent findings suggest that membrane partners facilitate this tethering, providing a rationale for exploring conformation-specific antigen selection in the development of monoclonal antibodies, T-cell engagers (TCEs), and antibody-drug conjugates (ADCs).

Schematic of KLK2 Sequence and Structure[1][2]
Key Finding 1: KLK2 on the Tumor Cell Membrane is in the Active Form
KLK2 is initially synthesized as an inactive zymogen (pro-KLK2) containing a short N-terminal propeptide. This propeptide must undergo proteolytic cleavage at a specific arginine (Arg) residue to yield the catalytically active enzyme (active-form KLK2).
By coupling cell-surface protein enrichment with targeted, absolute quantitative mass spectrometry, the study utilized signature peptides generated by Trypsin/LysC digestion to distinguish and quantify pro-form versus active-form KLK2 on the plasma membrane. Recent findings suggest that virtually all membrane-associated KLK2 on VCaP cells exists predominantly in the active, mature conformation rather than the zymogen form.

Trypsin/LysC Cleavage Sites and Detection Results for Different Signature Peptides
Key Finding 2: SPINT1 and SPINT2 Act as Membrane Tethers for KLK2
Using visible-light proximity labeling for unbiased screening, combined with a whole-genome CRISPR resistance screen and co-immunoprecipitation (Co-IP) validation, the investigation demonstrated that the transmembrane serine protease inhibitors SPINT1 (HAI-1) and SPINT2 (HAI-2) form stable complexes with KLK2 at the tumor cell surface.
Recent findings suggest that SPINT1/2 mediate the membrane anchoring of KLK2. Flow cytometric analyses revealed that genetic knockout of either SPINT1 or SPINT2 in VCaP cells markedly downregulates membrane-bound KLK2 levels.

Flow Cytometric Analysis of the Effect of SPINT1 or SPINT2 Knockout on Cell-Surface KLK2 Levels (Top left: Wild Type; Top right: KLK2 KO; Bottom left: SPINT1 KO; Bottom right: SPINT2 KO)
Furthermore, in vitro biochemical assays corroborated that only active-form KLK2 forms a stable complex with SPINT1, whereas pro-KLK2 fails to bind, aligning with the observation that only mature KLK2 is enriched on the surfaceome.
Key Finding 3: Structural Modeling Identifies Key Salt-Bridge Interactions in the SPINT1 K1 Domain
SPINT1 is a type I transmembrane protein whose extracellular region comprises five discrete domains: MANEC, PKD-like, Kunitz domain 1 (K1), LDLRA, and Kunitz domain 2 (K2). Molecular docking models were utilized to characterize the interaction interfaces between individual SPINT1 domains and KLK2.
The resulting structural models indicate that a critical salt bridge forms between Arg225 (R225) of the SPINT1 K1 domain and Asp174 (D174) of KLK2. In contrast, the corresponding position in the K2 domain features a Lys residue (K225), which cannot establish an equivalent interaction under these parameters. Based on these computational and structural analyses, the K1 domain of SPINT1 is proposed to serve as the primary functional anchor mediating KLK2 cell-surface presentation.

Schematic of SPINT1 Domain Architecture (left) and Molecular Docking Model of the KLK2-SPINT1 Complex (right)[2]
Antigen Selection: Free KLK2 vs. The KLK2-SPINT1 Complex
Following the identification of SPINT1 as a putative membrane anchor, comparative immunization studies yielded striking findings:
- Antibodies generated using free, recombinant KLK2 as the immunogen exhibited non-specific binding to KLK2-negative DU145 cells and failed to specifically recognize native KLK2 on VCaP cells.
- In contrast, antibodies generated against the KLK2-SPINT1 complex selectively bound KLK2-positive VCaP cells with negligible binding to DU145 cells.
These findings provide a rationale for exploring complex-specific epitopes in therapeutic discovery. For modalities such as monoclonal antibodies, TCEs, and ADCs, targeting the native, membrane-associated conformation of KLK2—rather than soluble, uncomplexed forms—could significantly improve tumor-cell selectivity and minimize on-target, off-tumor binding to circulating KLK2 in peripheral blood.

Flow Cytometric Binding Profiles of Antibodies Raised Against Free KLK2 (top) vs. the KLK2-SPINT1 Complex (bottom)
KACTUS Supplies High-Quality KLK2-SPINT Fusion Proteins and Recombinant Antigens
Because differences in target conformation can dictate whether a candidate antibody recognizes cell-surface KLK2, precise antigen design is foundational to preclinical success.
To support targeted drug discovery, KACTUS provides specialized KLK2-SPINT1 Kunitz Domain 1 fusion proteins designed to present the native-like conformational epitope found on tumor cell membranes. Additionally, KACTUS offers active and pro-form KLK2, as well as full extracellular domain (ECD) proteins for SPINT1 and SPINT2 across human, cynomolgus monkey, and rodent species, enabling flexible in vitro complex assembly, cross-species reactivity profiling, and high-throughput screening.

Immobilized Human KLK2 fused SPINT1 Kunitz Domain 1, His Tag at 0.5μg/ml(100μl/well) on the plate. Dose response curve for Pasritamig, hFc Tag with the EC50 of 4.9ng/ml determined by ELISA.

Immobilized Biotinylated Human KLK2 fused SPINT1 Kunitz Domain 1, His Avi Tag at 0.5μg/ml(100μl/well) on the streptavidin precoated plate(5μg/ml). Dose response curve for Pasritamig, hFc Tag with the EC50 of 4.3ng/ml determined by ELISA.

Immobilized Human Kallikrein 2, No Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Anti-Kallikrein 2 Antibody, hFc Tag with the EC50 of 3.3ng/ml determined by ELISA.

Human Kallikrein 2, Tag-Free (Active Form) Enzyme Activity. Measured by its ability to cleave the fluorogenic peptide substrate PFR-AMC. The specific activity is >450 pmol/min/μg.

Immobilized Rhesus macaque Kallikrein 2, His Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for Pasritamig with the EC50 of 12.5 ng/ml determined by ELISA .
Product List
|
Catalog Number |
Product Name |
Tag |
|
KLK-HM4S1 |
Human KLK2 fused SPINT1 Kunitz Domain 1 Protein |
His-Avi Tag |
|
KLK-HM4S1B |
Biotinylated Human KLK2 fused SPINT1 Kunitz Domain 1 Protein |
His-Avi Tag |
|
Human Kallikrein 2/KLK2 Protein (active form) |
Tag-Free |
|
|
Human Kallikrein 2/KLK2 Protein (active form) |
His Tag |
|
|
Human Kallikrein 2/KLK2 Protein (pro form) |
His Tag |
|
|
Biotinylated Human Kallikrein 2/KLK2 Protein (active form) |
His-Avi Tag |
|
|
Rhesus macaque Kallikrein 2/KLK2 Protein |
His Tag |
|
|
Rat Kallikrein 2/KLK2 Protein |
His Tag |
|
|
Human HAI-1/SPINT1 Protein |
His Tag |
|
|
Human HAI-2/SPINT2 Protein |
His Tag |
References
[1] KLK2 - Kallikrein-2 - Homo sapiens (Human) | UniProtKB
[2] Skala W, Utzschneider DT, Magdolen V, Debela M, Guo S, Craik CS, Brandstetter H, Goettig P. Structure-function analyses of human kallikrein-related peptidase 2 establish the 99-loop as master regulator of activity. J Biol Chem. 2014 Dec 5;289(49):34267-83. doi: 10.1074/jbc.M114.598201. Epub 2014 Oct 16. PMID: 25326387; PMCID: PMC4256358.
[3] Shen F, Smith R, McDevitt T, Menard K, Tian S, Chu G, Chaudhary R, McCann J, Oyer H, Wang SC, Max S, Francis P, Kelly WK, Drake CG. Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer. Clin Cancer Res. 2025 Nov 3;31(21):4543-4556. doi: 10.1158/1078-0432.CCR-25-0950. PMID: 40627156; PMCID: PMC12580770.